Breaking News

TriLink BioTechnologies Unveils Latest mRNA Capping Technology

Newest cap analog product improves mRNA potency with greater protein expression.

TriLink Bio Technologies, a Maravai LifeSciences company and global provider of life science reagents and services, has launched its newest cap analog, CleanCap M6 . The latest CleanCap analog is expected to help developers and researchers maximize the impact of their mRNA therapeutics and vaccines while reducing overall manufacturing costs, bringing medicines to market faster. With the introduction of the CleanCap M6 technology, legacy capping methods like enzymatic and ARCA may be a thing o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters